Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365567 | 1.00 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL6008318 | 0.85 | NPC1 (0.32) | NPC1 | |
| SCHEMBL18181139 | 0.84 | EGLN1 (0.39) | — | |
| SCHEMBL12003040 | 0.84 | KMT2A (0.32) | — | |
| SCHEMBL23257662 | 0.84 | — | — | |
| SCHEMBL1874578 | 0.82 | EGLN1 (0.34) | NPC1 | |
| SCHEMBL1874711 | 0.81 | PGR (0.34) | NPC1 | |
| SCHEMBL30468535 | 0.81 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL21904287 | 0.81 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL722670 | 0.81 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-11400081-B2 | Compounds | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-08-02 | — | — | US | disclosed |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3880308-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880679-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007016087-A2 | HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | NPC1 740/4885DGAT1 4351/4885 |
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | NPC1 805/4885DGAT1 4788/4885 |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | NPC1 609/4885DGAT1 4510/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | NPC1 1499/4885DGAT1 4851/4885 |
| US-11400081-B2 | Compounds | MRGPRX2, MC2R, ADM2 | NPC1 805/4885DGAT1 4788/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | NPC1 596/4885DGAT1 4421/4885 |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | NPC1 1561/4885DGAT1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.